Back to Search
Start Over
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
- Source :
- The Lancet; October 2017, Vol. 390 Issue: 10105 p1833-1842, 10p
- Publication Year :
- 2017
-
Abstract
- Inflammation in the tumour microenvironment mediated by interleukin 1β is hypothesised to have a major role in cancer invasiveness, progression, and metastases. We did an additional analysis in the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), a randomised trial of the role of interleukin-1β inhibition in atherosclerosis, with the aim of establishing whether inhibition of a major product of the Nod-like receptor protein 3 (NLRP3) inflammasome with canakinumab might alter cancer incidence.
Details
- Language :
- English
- ISSN :
- 01406736 and 1474547X
- Volume :
- 390
- Issue :
- 10105
- Database :
- Supplemental Index
- Journal :
- The Lancet
- Publication Type :
- Periodical
- Accession number :
- ejs43538148
- Full Text :
- https://doi.org/10.1016/S0140-6736(17)32247-X